NEUROSCIENTIFIC BIOPHARMACEUTICALS LTD - Announcements

8.33%

16.5¢

Market Cap $54.87M

Healthcare Biotechnology

NeuroScientific Biopharmaceuticals Limited is an Australia-based company, which is... NeuroScientific Biopharmaceuticals Limited is an Australia-based company, which is engaged in developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The Company's product portfolio includes EmtinB, a therapeutic peptide initially targeting glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn and EmtinBn). EmtinB is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinB is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body's innate immune response to cell injury. Its StemSmart is a global patented technology engaged in manufacturing cell products. The use of its proprietary StemSmart technology in a special access program for fistulising Crohn’s disease.More

ASX:PAR

This stock could have something close to a cure for osteoarthritis. Paradigm Biopharmaceuticals (ASX:PAR) is a late-stage drug development company working first and foremost to create a superior treatment for osteoarthritis.

Announcements

Filter Results

All Price Sensitive Only

NSB	Positive treatment effect in MS animal study	PRICE SENSITIVE	14/03/23	1.06MB	Share
NSB	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/23	1.2MB	Share
NSB	Notification of cessation of securities - NSB		06/02/23	22.16KB	Share
NSB	Investor Update Presentation		03/02/23	1.51MB	Share
NSB	Investor Update Webinar		02/02/23	157.11KB	Share
NSB	R&D Tax Incentive Refund Received	PRICE SENSITIVE	02/02/23	116.37KB	Share
NSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/23	283.22KB	Share
NSB	Patent Application - Updated Announcement		15/12/22	482KB	Share
NSB	NSB files new patent	PRICE SENSITIVE	05/12/22	434.32KB	Share
NSB	Results of Meeting		24/11/22	308.92KB	Share
NSB	Chair's address to shareholders & AGM presentation		24/11/22	1.61MB	Share
NSB	Appointment of Interim CEO	PRICE SENSITIVE	23/11/22	170.98KB	Share
NSB	Executive Management Changes		15/11/22	142.13KB	Share
NSB	NSB receives R&D Advance & Overseas Finding		14/11/22	156.12KB	Share
NSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/22	283.14KB	Share
NSB	Notice of Annual General Meeting		21/10/22	367.17KB	Share
NSB	Investor Update Presentation	PRICE SENSITIVE	20/09/22	1.05MB	Share
NSB	Investor Update Webinar		19/09/22	152.82KB	Share
NSB	Final Director's Interest Notice - Liddelow		16/09/22	7.06KB	Share
NSB	CEO Resignation	PRICE SENSITIVE	09/09/22	124.53KB	Share
NSB	Investor Update Webinar		07/09/22	117.82KB	Share
NSB	HREC decision to not approve Phase I Clinical Trial	PRICE SENSITIVE	07/09/22	129.59KB	Share
NSB	Corporate Governance Statement		30/08/22	212.45KB	Share
NSB	Appendix 4G		30/08/22	260.06KB	Share
NSB	NeuroScientific releases FY2022 Results	PRICE SENSITIVE	30/08/22	223.9KB	Share
NSB	2022 Annual Report and Appendix 4E	PRICE SENSITIVE	30/08/22	1.85MB	Share
NSB	R&D Tax Incentive Refund Received	PRICE SENSITIVE	17/08/22	139.55KB	Share
NSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/07/22	292.44KB	Share
NSB	HREC Submission for Phase I Clinical Trial	PRICE SENSITIVE	12/07/22	138.38KB	Share
NSB	First Subject Recruited for Early-Phase Clinical Trial	PRICE SENSITIVE	30/06/22	142.11KB	Share
NSB	Notification of cessation of securities - NSB		27/06/22	21.74KB	Share
NSB	Company Presentation - Gold Coast Investment Showcase		22/06/22	2.33MB	Share
NSB	Clarification of Results in MS Animal Study		22/06/22	231.32KB	Share
NSB	Notification regarding unquoted securities - NSB		21/06/22	29.66KB	Share
NSB	Issue of Employee Options		21/06/22	214.24KB	Share
NSB	Positive results in MS animal study	PRICE SENSITIVE	15/06/22	147.01KB	Share
NSB	Ethics Approval Granted for Early-Phase Clinical Trial	PRICE SENSITIVE	07/06/22	140.53KB	Share
NSB	HREC Submission for early-phase Clinical Trial	PRICE SENSITIVE	11/05/22	149.59KB	Share
NSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/04/22	284.15KB	Share
NSB	Positive safety result supports advance to clinical trials	PRICE SENSITIVE	13/04/22	144.93KB	Share
NSB	NSB Enhances Management Team		01/04/22	143.91KB	Share
NSB	Company Presentation		24/03/22	1.13MB	Share
NSB	NSB presenting at Broker Briefing Investor Webinar		23/03/22	139.34KB	Share
NSB	New data demonstrates EmtinB activity in autoimmune diseases	PRICE SENSITIVE	11/03/22	258.11KB	Share
NSB	NSB 1HY22 Key Activity Highlights	PRICE SENSITIVE	28/02/22	223.32KB	Share
NSB	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/22	885.91KB	Share
NSB	Successful completion of key studies in lead up to Phase I	PRICE SENSITIVE	08/02/22	144.51KB	Share
NSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/22	300.57KB	Share
NSB	Positive off-target safety assessment of EmtinB	PRICE SENSITIVE	24/12/21	144.05KB	Share
NSB	Positive results in biomarker characterisation of Emtins	PRICE SENSITIVE	21/12/21	421.77KB	Share
NSB	Change of Registry Address		20/12/21	152.9KB	Share
NSB	Change of Director's Interest Notice		13/12/21	262.34KB	Share
NSB	Change of Director's Interest Notice		13/12/21	260.77KB	Share
NSB	Change of Director's Interest Notice		13/12/21	263.44KB	Share
NSB	Change of Director's Interest Notice		13/12/21	260.58KB	Share
NSB	Notification regarding unquoted securities - NSB		08/12/21	27.27KB	Share
NSB	Notification regarding unquoted securities - NSB		08/12/21	27.35KB	Share
NSB	Investor Webinar Presentation		03/12/21	1.32MB	Share
NSB	NSB partners with leading diffusion MRI company Imeka		22/11/21	291.09KB	Share
NSB	Investor Webinar Presentation		18/11/21	1.18MB	Share
NSB	Adoption of New Constitution		11/11/21	743.08KB	Share
NSB	Results of Meeting		11/11/21	216.05KB	Share
NSB	Chairman's Address to Shareholders		11/11/21	1.14MB	Share
NSB	NSB Partners with Biospective for MS Studies		02/11/21	221.66KB	Share
NSB	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/10/21	279.9KB	Share
NSB	Company Presentation - updated		26/10/21	2.23MB	Share
NSB	Company Presentation		26/10/21	2.24MB	Share
NSB	Completion of Safety Pharmacology Studies	PRICE SENSITIVE	18/10/21	143.03KB	Share
NSB	Proposed issue of securities - NSB		11/10/21	26.58KB	Share
NSB	Notice of Annual General Meeting/Proxy Form		11/10/21	633.44KB	Share
NSB	Appendix 4G		23/09/21	258.32KB	Share
NSB	Corporate Governance Statement		23/09/21	220.29KB	Share
NSB	Date of AGM & Closing Date for Director Nominations		21/09/21	154.33KB	Share
NSB	Broker Briefing Investor Webinar		08/09/21	121.17KB	Share
NSB	Company Presentation		03/09/21	1.91MB	Share
NSB	Investor Webinar		03/09/21	110.21KB	Share
NSB	NSB Receives R&D Advance & Overseas Finding	PRICE SENSITIVE	03/09/21	114.12KB	Share
NSB	Positive Results in Multiple Sclerosis Study	PRICE SENSITIVE	31/08/21	248.06KB	Share
NSB	2021 Annual Report and Appendix 4E	PRICE SENSITIVE	27/08/21	910.83KB	Share
NSB	NSB appoints International Scientific Advisors		24/08/21	138.79KB	Share
NSB	Results from Pulmonary Studies Clarification	PRICE SENSITIVE	20/08/21	159.86KB	Share
NSB	Trading Halt	PRICE SENSITIVE	19/08/21	587.81KB	Share
NSB	Pause in Trading	PRICE SENSITIVE	19/08/21	118.08KB	Share
NSB	Results from Pulmonary Studies	PRICE SENSITIVE	19/08/21	161.11KB	Share
NSB	Quarterly Update and Appendix 4C	PRICE SENSITIVE	30/07/21	349.07KB	Share
NSB	Change of Director's Interest Notice		13/07/21	255.96KB	Share
NSB	Successful completion of pivotal ocular safety study	PRICE SENSITIVE	01/07/21	169.24KB	Share
NSB	Trading Halt	PRICE SENSITIVE	30/06/21	589.64KB	Share
NSB	Pause in Trading	PRICE SENSITIVE	30/06/21	117.12KB	Share
NSB	Initial Director's Interest Notice		28/06/21	230.76KB	Share
NSB	Gold Coast Investment Showcase Presentation		23/06/21	2.1MB	Share
NSB	NSB partners with Linear Research for Phase I Clinical Study	PRICE SENSITIVE	23/06/21	174.21KB	Share
NSB	Proposed issue of securities - NSB		22/06/21	26.99KB	Share
NSB	Appointment of Non-executive Chairman		22/06/21	177.97KB	Share
NSB	R&D Tax Rebate Received	PRICE SENSITIVE	31/05/21	106.28KB	Share
NSB	Appendix 3G		27/05/21	273.61KB	Share
NSB	Final Director's Interest Notice		20/05/21	248.38KB	Share
NSB	Director Appointment/Resignation		18/05/21	101.14KB	Share
NSB	Change of Director's Interest Notice		18/05/21	213.78KB	Share
NSB	Change of Director's Interest Notice		18/05/21	213.04KB	Share

NSB Positive treatment effect in MS animal study
14/03/23	PRICE SENSITIVE	1.06MB	Share
NSB Half Yearly Report and Accounts
28/02/23	PRICE SENSITIVE	1.2MB	Share
NSB Notification of cessation of securities - NSB
06/02/23		22.16KB	Share
NSB Investor Update Presentation
03/02/23		1.51MB	Share
NSB Investor Update Webinar
02/02/23		157.11KB	Share
NSB R&D Tax Incentive Refund Received
02/02/23	PRICE SENSITIVE	116.37KB	Share
NSB Quarterly Activities/Appendix 4C Cash Flow Report
31/01/23	PRICE SENSITIVE	283.22KB	Share
NSB Patent Application - Updated Announcement
15/12/22		482KB	Share
NSB NSB files new patent
05/12/22	PRICE SENSITIVE	434.32KB	Share
NSB Results of Meeting
24/11/22		308.92KB	Share
NSB Chair's address to shareholders & AGM presentation
24/11/22		1.61MB	Share
NSB Appointment of Interim CEO
23/11/22	PRICE SENSITIVE	170.98KB	Share
NSB Executive Management Changes
15/11/22		142.13KB	Share
NSB NSB receives R&D Advance & Overseas Finding
14/11/22		156.12KB	Share
NSB Quarterly Activities/Appendix 4C Cash Flow Report
31/10/22	PRICE SENSITIVE	283.14KB	Share
NSB Notice of Annual General Meeting
21/10/22		367.17KB	Share
NSB Investor Update Presentation
20/09/22	PRICE SENSITIVE	1.05MB	Share
NSB Investor Update Webinar
19/09/22		152.82KB	Share
NSB Final Director's Interest Notice - Liddelow
16/09/22		7.06KB	Share
NSB CEO Resignation
09/09/22	PRICE SENSITIVE	124.53KB	Share
NSB Investor Update Webinar
07/09/22		117.82KB	Share
NSB HREC decision to not approve Phase I Clinical Trial
07/09/22	PRICE SENSITIVE	129.59KB	Share
NSB Corporate Governance Statement
30/08/22		212.45KB	Share
NSB Appendix 4G
30/08/22		260.06KB	Share
NSB NeuroScientific releases FY2022 Results
30/08/22	PRICE SENSITIVE	223.9KB	Share
NSB 2022 Annual Report and Appendix 4E
30/08/22	PRICE SENSITIVE	1.85MB	Share
NSB R&D Tax Incentive Refund Received
17/08/22	PRICE SENSITIVE	139.55KB	Share
NSB Quarterly Activities/Appendix 4C Cash Flow Report
29/07/22	PRICE SENSITIVE	292.44KB	Share
NSB HREC Submission for Phase I Clinical Trial
12/07/22	PRICE SENSITIVE	138.38KB	Share
NSB First Subject Recruited for Early-Phase Clinical Trial
30/06/22	PRICE SENSITIVE	142.11KB	Share
NSB Notification of cessation of securities - NSB
27/06/22		21.74KB	Share
NSB Company Presentation - Gold Coast Investment Showcase
22/06/22		2.33MB	Share
NSB Clarification of Results in MS Animal Study
22/06/22		231.32KB	Share
NSB Notification regarding unquoted securities - NSB
21/06/22		29.66KB	Share
NSB Issue of Employee Options
21/06/22		214.24KB	Share
NSB Positive results in MS animal study
15/06/22	PRICE SENSITIVE	147.01KB	Share
NSB Ethics Approval Granted for Early-Phase Clinical Trial
07/06/22	PRICE SENSITIVE	140.53KB	Share
NSB HREC Submission for early-phase Clinical Trial
11/05/22	PRICE SENSITIVE	149.59KB	Share
NSB Quarterly Activities/Appendix 4C Cash Flow Report
29/04/22	PRICE SENSITIVE	284.15KB	Share
NSB Positive safety result supports advance to clinical trials
13/04/22	PRICE SENSITIVE	144.93KB	Share
NSB NSB Enhances Management Team
01/04/22		143.91KB	Share
NSB Company Presentation
24/03/22		1.13MB	Share
NSB NSB presenting at Broker Briefing Investor Webinar
23/03/22		139.34KB	Share
NSB New data demonstrates EmtinB activity in autoimmune diseases
11/03/22	PRICE SENSITIVE	258.11KB	Share
NSB NSB 1HY22 Key Activity Highlights
28/02/22	PRICE SENSITIVE	223.32KB	Share
NSB Half Yearly Report and Accounts
28/02/22	PRICE SENSITIVE	885.91KB	Share
NSB Successful completion of key studies in lead up to Phase I
08/02/22	PRICE SENSITIVE	144.51KB	Share
NSB Quarterly Activities/Appendix 4C Cash Flow Report
31/01/22	PRICE SENSITIVE	300.57KB	Share
NSB Positive off-target safety assessment of EmtinB
24/12/21	PRICE SENSITIVE	144.05KB	Share
NSB Positive results in biomarker characterisation of Emtins
21/12/21	PRICE SENSITIVE	421.77KB	Share
NSB Change of Registry Address
20/12/21		152.9KB	Share
NSB Change of Director's Interest Notice
13/12/21		262.34KB	Share
NSB Change of Director's Interest Notice
13/12/21		260.77KB	Share
NSB Change of Director's Interest Notice
13/12/21		263.44KB	Share
NSB Change of Director's Interest Notice
13/12/21		260.58KB	Share
NSB Notification regarding unquoted securities - NSB
08/12/21		27.27KB	Share
NSB Notification regarding unquoted securities - NSB
08/12/21		27.35KB	Share
NSB Investor Webinar Presentation
03/12/21		1.32MB	Share
NSB NSB partners with leading diffusion MRI company Imeka
22/11/21		291.09KB	Share
NSB Investor Webinar Presentation
18/11/21		1.18MB	Share
NSB Adoption of New Constitution
11/11/21		743.08KB	Share
NSB Results of Meeting
11/11/21		216.05KB	Share
NSB Chairman's Address to Shareholders
11/11/21		1.14MB	Share
NSB NSB Partners with Biospective for MS Studies
02/11/21		221.66KB	Share
NSB Quarterly Activities/Appendix 4C Cash Flow Report
29/10/21	PRICE SENSITIVE	279.9KB	Share
NSB Company Presentation - updated
26/10/21		2.23MB	Share
NSB Company Presentation
26/10/21		2.24MB	Share
NSB Completion of Safety Pharmacology Studies
18/10/21	PRICE SENSITIVE	143.03KB	Share
NSB Proposed issue of securities - NSB
11/10/21		26.58KB	Share
NSB Notice of Annual General Meeting/Proxy Form
11/10/21		633.44KB	Share
NSB Appendix 4G
23/09/21		258.32KB	Share
NSB Corporate Governance Statement
23/09/21		220.29KB	Share
NSB Date of AGM & Closing Date for Director Nominations
21/09/21		154.33KB	Share
NSB Broker Briefing Investor Webinar
08/09/21		121.17KB	Share
NSB Company Presentation
03/09/21		1.91MB	Share
NSB Investor Webinar
03/09/21		110.21KB	Share
NSB NSB Receives R&D Advance & Overseas Finding
03/09/21	PRICE SENSITIVE	114.12KB	Share
NSB Positive Results in Multiple Sclerosis Study
31/08/21	PRICE SENSITIVE	248.06KB	Share
NSB 2021 Annual Report and Appendix 4E
27/08/21	PRICE SENSITIVE	910.83KB	Share
NSB NSB appoints International Scientific Advisors
24/08/21		138.79KB	Share
NSB Results from Pulmonary Studies Clarification
20/08/21	PRICE SENSITIVE	159.86KB	Share
NSB Trading Halt
19/08/21	PRICE SENSITIVE	587.81KB	Share
NSB Pause in Trading
19/08/21	PRICE SENSITIVE	118.08KB	Share
NSB Results from Pulmonary Studies
19/08/21	PRICE SENSITIVE	161.11KB	Share
NSB Quarterly Update and Appendix 4C
30/07/21	PRICE SENSITIVE	349.07KB	Share
NSB Change of Director's Interest Notice
13/07/21		255.96KB	Share
NSB Successful completion of pivotal ocular safety study
01/07/21	PRICE SENSITIVE	169.24KB	Share
NSB Trading Halt
30/06/21	PRICE SENSITIVE	589.64KB	Share
NSB Pause in Trading
30/06/21	PRICE SENSITIVE	117.12KB	Share
NSB Initial Director's Interest Notice
28/06/21		230.76KB	Share
NSB Gold Coast Investment Showcase Presentation
23/06/21		2.1MB	Share
NSB NSB partners with Linear Research for Phase I Clinical Study
23/06/21	PRICE SENSITIVE	174.21KB	Share
NSB Proposed issue of securities - NSB
22/06/21		26.99KB	Share
NSB Appointment of Non-executive Chairman
22/06/21		177.97KB	Share
NSB R&D Tax Rebate Received
31/05/21	PRICE SENSITIVE	106.28KB	Share
NSB Appendix 3G
27/05/21		273.61KB	Share
NSB Final Director's Interest Notice
20/05/21		248.38KB	Share
NSB Director Appointment/Resignation
18/05/21		101.14KB	Share
NSB Change of Director's Interest Notice
18/05/21		213.78KB	Share
NSB Change of Director's Interest Notice
18/05/21		213.04KB	Share

REFRESH

First 2 3

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 16.5¢		Change -0.015(8.33%)		Mkt cap ! $54.87M

Open	High	Low	Value	Volume
17.5¢	18.0¢	16.5¢	$35.84K	210.2K

Buyers (Bids)

No.	Vol.	Price($)
3	74350	16.5¢

Sellers (Offers)

Price($)	Vol.	No.
18.0¢	223089	4

View Market Depth

No.	Vol.	Price($)
3	74350	0.165
5	211876	0.160
2	42209	0.155
4	30574	0.150
1	300000	0.145

Price($)	Vol.	No.
0.180	223089	4
0.185	86585	3
0.190	200000	1
0.195	38000	3
0.200	374501	5

Last trade - 16.10pm 18/09/2025 (20 minute delay)


Last 16.5¢		Change -0.015 ( 2.94 %)
Open	High	Low	Volume
17.5¢	17.5¢	16.5¢	177708
Last updated 15.22pm 18/09/2025 ?

NSB (ASX) Chart

NEUROSCIENTIFIC BIOPHARMACEUTICALS LTD - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories